David Taber, United States
6-Month Outcomes of a Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

IRFAN MOINUDDIN, United States
CMV T-Cell Immunity Assay Based Guidance to Interrupt Prophylaxis in Intermediate Risk Kidney Transplant Patients

Kennedy Concannon, United States
Low-Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant

Chelsea Morinishi, United States
Risk Factors and Real-World Implications of CMV Resistance Mutations After Treatment with Maribavir or Foscarnet for Resistant and Refractory CMV

Franco Citterio, Italy
Prevention of CMV and BKV in De Novo Kidney Transplant Recipients Immunosuppressed with the Combination of Low Dose Tacrolimus and Everolimus

Zachary Yetmar, United States
Effect of Secondary Prophylaxis on the Risk of Recurrent Cytomegalovirus Infection Among Solid Organ Transplant Recipients

Bongha Shin, United States
Impaired CMV-Specific CD8⁺ T Cell Responses Correlate with Increased CMV Viremia in Kidney Transplant Recipients: A Comparative Analysis of Adult and Pediatric Patients

Harry Pickering, United Kingdom
Pre-Viremic, Multi-Omic Immune Signatures of Cytomegalovirus Infection in Kidney Transplant Recipients